Navigation Links
SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
Date:3/27/2008

a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs or commence IND enabling activities or preclinical or clinical studies in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or clinical trials. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE SGX Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
4. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
5. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
6. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
7. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
8. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
9. Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
10. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) fertilizers ... high prices in 2008. However, the situation has stabilised ... gaining momentum now. , To date, the world annual ... thousand tonnes. No considerable growth was registered in the ... during 2012-2013, registering 11% growth as against the period ...
(Date:3/27/2015)... Mich. , March 27, 2015  Neogen Corporation ... LLC, has adopted a prearranged trading plan in accordance ... Herbert , Chairman and CEO of Neogen Corporation, is ... of Neogen Corporation common stock. Herbert does ... disclosure was appropriate. The filing is only for a ...
(Date:3/27/2015)... March 27, 2015  Peter Walter was chosen as ... his pioneering work on how proteins are transported between ... regulatory mechanism that cells use to handle stress tied ... a professor of biochemistry at the University of California, ... a range of human diseases related to defective protein ...
(Date:3/27/2015)... , March 27, 2015 WuXi ... leading open-access R&D capability and technology platform company ... industries, announced today that an Investigational New Drug ... antibody for rheumatoid arthritis has been accepted for ... (CFDA).  In September 2012, MedImmune, ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Neogen CEO adopts 10b5-1 Trading Plan 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3
... the Phase III Clinical Development and ... of THR-100 in Developing Countries, LEUVEN, Belgium, ... biotechnology company focused on vascular disease, today,announced the ... International Limited (Hyderabad, India) for the manufacture of,THR-100, ...
... Collaboration With CDC to Ensure US,s Preparedness ... Public Health Emergency, CAMBRIDGE, England and CAMBRIDGE, ... a leading,vaccine company, announced today that the US ... (Smallpox (Vaccinia) Vaccine, Live) vaccine,for protection against smallpox. ...
... Sept. 3 Leading neurosurgical device,developer Elekta ... and treatment devices, along with clinical workflow ... at the European,Association of Neurosurgical Societies (EANS) ... neurosurgeons and related medical professionals,will gather at ...
Cached Biology Technology:ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 2FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 3FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 4FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 5Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 2Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 3Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 4
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
(Date:3/10/2015)... March 10, 2015 Transforming How ... "Personalized Medicine in Human Space Flight" by ... J. Goodwin , Ph.D. was recently featured by Springer ... two years. Specifically, "Personalized Medicine in Human ... papers published in 2013 and 2014 from Springer in ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... Treatment with the oral antiviral Tamiflu (oseltamivir) and ... be one of the most cost-effective strategies for ... According to modelling research presented by Beate Sander, ... sufficient to cover 65% of a country’s population ...
... serve as biofactories for the production of various beneficial ... new genes into mushrooms. , "There has always been ... choice platform for the mass production of commercially valuable ... B. Swayne Chair in spawn science and professor of ...
... causes disease have come to a simple conclusion -- ... might help them find a new treatment for what can ... genes responsible for toxin production only seem to be expressed ... with the view that most disease-causing bacteria express their pathogenicity ...
Cached Biology News:Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention 2Modified mushrooms may yield human drugs 2Understanding why C. difficile causes disease -- it's hungry 2
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
... selection system for recombinant identification. Recombinant selection ... need for costly color screening. This quick ... accuracy in recombinant selection. pLivSelect is also ... This cloning kit is customized as ...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: